Fruquintinib Production Cost Reports

The report provides a detailed analysis essential for establishing a Fruquintinib production plant. It encompasses all critical aspects necessary for Fruquintinib production, including the cost of Fruquintinib production, Fruquintinib plant cost, Fruquintinib production costs, and the overall Fruquintinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Fruquintinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Fruquintinib is a medication used to treat adults with metastatic colorectal cancer that has spread from the colon or rectum to other parts of the body. This medication is a vascular endothelial growth factor (VEGF) receptor inhibitor, only administered to individuals who have already received many chemotherapy treatments, such as those based on oxaliplatin, fluoropyrimidine, and irinotecan. Furthermore, it is recommended for patients whose cancer contains specific genetic markers and who have also received anti-EGFR therapy, in addition to those who have taken anti-VEGF therapy (which targets blood arteries that nourish the tumor).

The procurement of Fruquintinib is influenced by its application in the pharmaceutical and medical industries as an anticancer medication used to treat colorectal cancer. The widespread occurrence of colorectal cancer is significantly increasing the demand for Fruquintinib. When used as an optional treatment for patients with advanced STS who did not react to numerous lines of therapy, it has been demonstrated to have good safety and efficacy, which has increased its market demand. Fruquintinib has demonstrated success not only in treating metastatic colorectal cancer but also in treating other solid tumors, such as gastric and lung malignancies.

Its expanding range of therapeutic uses drives up demand for it in the market and enhances the interest of medical professionals searching for efficient cancer treatment solutions. Fruquintinib's market expansion has been aided by clinical trials that show it is both effective and well-tolerated in patients with advanced malignancies. Overall, industrial Fruquintinib procurement is influenced by its application in the pharmaceutical and medical industries, good safety and efficacy, efficacy for multiple cancers, better tolerability, and regulatory approvals.

Raw Material for Fruquintinib Production

According to the Fruquintinib production plant project report, the key raw material used in the production of Fruquintinib includes 4-chloroquinazoline.

Production Process of Fruquintinib

The extensive Fruquintinib production cost report consists of the following major industrial production process:

• Production from 4-chloroquinazoline: The nucleophilic aromatic substitution is the first step in the production process of Fruquintinib. In this procedure, 6-hydroxybenzofurane and 4-chloroquinazoline interact in an alkaline environment. Finally, the hydroxyl group of 6-hydroxybenzofurane replaces a chlorine atom in 4-chloroquinazoline to produce Fruquintinib.

Fruquintinib, commercially known as Fruzaqla, is a white to off-white crystalline powder having the molecular formula C21H19N3O5 and a molecular weight of 393.4 g/mol. It has an estimated water solubility of 0.0803 mg/mL. It is soluble in DMSO. It has a log P value of 3.12. The value of its dissociation constant, pKa, is 14.99. It is a member of the class of drugs called quinazolines.

It can be taken orally. It belongs to the class of aromatic ethers, quinazolines, 1-benzofurans, and secondary carboxamides. It inhibits the vascular endothelial growth factor receptors (VEGFRs) and may have anti-angiogenic and anticancer effects. It is used to treat colorectal cancer.